Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15075rdf:typepubmed:Citationlld:pubmed
pubmed-article:15075lifeskim:mentionsumls-concept:C0006467lld:lifeskim
pubmed-article:15075lifeskim:mentionsumls-concept:C0040615lld:lifeskim
pubmed-article:15075lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:15075lifeskim:mentionsumls-concept:C0441712lld:lifeskim
pubmed-article:15075pubmed:issue3lld:pubmed
pubmed-article:15075pubmed:dateCreated1977-5-25lld:pubmed
pubmed-article:15075pubmed:abstractTextButaclamol (1.0-0.1 mg kg-1, i.p.) and spiroperidol (1-0-0-5 mg kg-1, i.p.) but not (-)-butaclamol (15 mg kg-1, i.p.), blocked the hyperactivity induced in rats by tranylcypromine-L-tryptophan pretreatment. Neither butaclamol nor spiroperidol altered the accumulation of brain 5-HT following parglyine or the decline of brain 5-HT following inhibition with the tryptophan hydroxylase inhibitor alpha-propyldopacetamide thus indicating that butaclamol and spiroperidol do not affect either the synthesis or the turnover of brain 5-HT. It is concluded that the antagonism of the tranylcypromise-L-tryptophan-induced hyperactivity by butaclamol and spiroperidol is due to their blockade of dopaminergic receptors rather than an action on neuronal serotoninergic mechanisms.lld:pubmed
pubmed-article:15075pubmed:languageenglld:pubmed
pubmed-article:15075pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15075pubmed:citationSubsetIMlld:pubmed
pubmed-article:15075pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15075pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15075pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15075pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15075pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15075pubmed:statusMEDLINElld:pubmed
pubmed-article:15075pubmed:monthMarlld:pubmed
pubmed-article:15075pubmed:issn0022-3573lld:pubmed
pubmed-article:15075pubmed:authorpubmed-author:LippmannWWlld:pubmed
pubmed-article:15075pubmed:authorpubmed-author:PugsleyT ATAlld:pubmed
pubmed-article:15075pubmed:issnTypePrintlld:pubmed
pubmed-article:15075pubmed:volume29lld:pubmed
pubmed-article:15075pubmed:ownerNLMlld:pubmed
pubmed-article:15075pubmed:authorsCompleteYlld:pubmed
pubmed-article:15075pubmed:pagination135-8lld:pubmed
pubmed-article:15075pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:15075pubmed:meshHeadingpubmed-meshheading:15075-An...lld:pubmed
pubmed-article:15075pubmed:meshHeadingpubmed-meshheading:15075-Ra...lld:pubmed
pubmed-article:15075pubmed:meshHeadingpubmed-meshheading:15075-Br...lld:pubmed
pubmed-article:15075pubmed:meshHeadingpubmed-meshheading:15075-Tr...lld:pubmed
pubmed-article:15075pubmed:meshHeadingpubmed-meshheading:15075-Se...lld:pubmed
pubmed-article:15075pubmed:meshHeadingpubmed-meshheading:15075-Ma...lld:pubmed
pubmed-article:15075pubmed:meshHeadingpubmed-meshheading:15075-Be...lld:pubmed
pubmed-article:15075pubmed:meshHeadingpubmed-meshheading:15075-Tr...lld:pubmed
pubmed-article:15075pubmed:meshHeadingpubmed-meshheading:15075-Mo...lld:pubmed
pubmed-article:15075pubmed:meshHeadingpubmed-meshheading:15075-St...lld:pubmed
pubmed-article:15075pubmed:meshHeadingpubmed-meshheading:15075-Di...lld:pubmed
pubmed-article:15075pubmed:meshHeadingpubmed-meshheading:15075-Sp...lld:pubmed
pubmed-article:15075pubmed:year1977lld:pubmed
pubmed-article:15075pubmed:articleTitleEffect of butaclamol, a new neuroleptic, on serotoninergic mechanisms.lld:pubmed
pubmed-article:15075pubmed:publicationTypeJournal Articlelld:pubmed